[8-K] PLUS THERAPEUTICS, Inc. Reports Material Event
Plus Therapeutics reported the results of its August 7, 2025 annual meeting. Of 60,490,101 shares outstanding at the June 18, 2025 record date, 29,973,272 shares were represented, constituting a quorum. All director nominees listed in the proxy were elected, with individual "for" votes generally in the range of 18.7 million to 18.94 million and 10,294,600 broker non-votes recorded for those director elections.
Stockholders approved several material proposals: authorization to potentially issue up to $50.0 million of common stock (plus up to $1.0 million as a commitment fee) to Lincoln Park Capital under the June 17, 2025 purchase agreement; discretionary authority for the board to effect a reverse stock split at any ratio between 1-for-2 and 1-for-250; an advisory approval of named executive officer compensation; and the fifth amendment and restatement of the 2020 Stock Incentive Plan.
Plus Therapeutics ha comunicato i risultati della sua assemblea annuale del 7 agosto 2025. Delle 60,490,101 azioni in circolazione alla data di record del 18 giugno 2025, sono state rappresentate 29,973,272 azioni, costituendo il quorum. Tutti i candidati al consiglio indicati nella delega sono stati eletti, con voti 'a favore' individuali generalmente compresi tra 18,7 milioni e 18,94 milioni e con 10,294,600 voti non espressi dai broker registrati per quelle elezioni.
Gli azionisti hanno approvato diverse proposte rilevanti: l'autorizzazione a emettere potenzialmente fino a $50,0 milioni di azioni ordinarie (pi霉 fino a $1,0 milioni come commissione di impegno) a Lincoln Park Capital ai sensi dell'accordo d'acquisto del 17 giugno 2025; l'autorit脿 discrezionale per il consiglio di effettuare un raggruppamento azionario a un rapporto compreso tra 1 contro 2 e 1 contro 250; un'approvazione consultiva della remunerazione dei dirigenti nominati; e la quinta modifica e riformulazione del Piano di Incentivi Azionari 2020.
Plus Therapeutics inform贸 los resultados de su junta anual del 7 de agosto de 2025. De las 60,490,101 acciones en circulaci贸n en la fecha de registro del 18 de junio de 2025, se representaron 29,973,272 acciones, constituyendo qu贸rum. Todos los candidatos al consejo incluidos en el poder fueron elegidos, con votos 'a favor' individuales generalmente en el rango de 18,7 millones a 18,94 millones y con 10,294,600 votos no emitidos por los intermediarios registrados en esas elecciones.
Los accionistas aprobaron varias propuestas importantes: la autorizaci贸n para emitir potencialmente hasta $50,0 millones de acciones ordinarias (m谩s hasta $1,0 millones como comisi贸n de compromiso) a Lincoln Park Capital seg煤n el acuerdo de compra del 17 de junio de 2025; la facultad discrecional del consejo para llevar a cabo una consolidaci贸n inversa de acciones en cualquier proporci贸n entre 1 por 2 y 1 por 250; la aprobaci贸n consultiva de la remuneraci贸n de los directivos nombrados; y la quinta enmienda y reformulaci贸n del Plan de Incentivos en Acciones de 2020.
Plus Therapeutics電� 2025雲� 8鞗� 7鞚� 鞐半 欤检＜齑濏殞 瓴瓣臣毳� 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 18鞚� 旮办鞙茧 氚滍枆欤检嫕靾� 60,490,101欤� 欷� 29,973,272欤缄皜 雽�響滊悩鞏� 鞝曥”靾橁皜 靹彪霅橃棃鞀惦媹雼�. 鞙勳瀯鞛レ棎 旮办灛霅� 氇摖 鞚挫偓 頉勲炒臧� 靹犾瀯霅橃棃鞙茧┌, 臧滊硠 '彀劚' 響滊姅 雽�觳措 鞎� 1,870毵寏1,894毵�欤� 氩旍渼鞓�瓿� 頃措嫻 鞚挫偓 靹犼卑鞐愳劀電� 10,294,600瓯挫潣 欷戧皽鞚�(敫岆旎�) 氙疙埇響滉皜 旮半霅橃棃鞀惦媹雼�.
欤检＜霌れ潃 鞐煬 欤检殧 鞎堦贝鞚� 鞀轨澑頄堨姷雼堧嫟. 2025雲� 6鞗� 17鞚� 毵れ垬瓿勳暯鞐� 霐半澕 Lincoln Park Capital鞐� 雽�頃� 氤错喌欤� 斓滊寑 $50.0 million(毂呾瀯 靾橃垬耄岆 斓滊寑 $1.0 million 於旉皜 臧�電�)鞚� 氚滍枆頃� 靾� 鞛堧姅 鞀轨澑; 鞚挫偓須岅皜 1雽赌2鞐愳劀 1雽赌250 靷澊鞚� 牍勳湪搿� 鞏胳牅霌犾 欤检嫕 氤戫暕(鞐硲頃�)鞚� 鞁ろ枆頃� 靾� 鞛堧姅 鞛焿甓�; 歆�氇� 鞛勳洂鞚� 氤挫垬鞐� 雽�頃� 甓岅碃鞝� 鞀轨澑; 氚� 2020雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉鞚� 鞝�5彀� 臧滌爼 氚� 鞛瀾靹� 霌膘澊 韽暔霅╇媹雼�.
Plus Therapeutics a annonc茅 les r茅sultats de son assembl茅e annuelle du 7 ao没t 2025. Sur les 60,490,101 actions en circulation 脿 la date d'enregistrement du 18 juin 2025, 29,973,272 actions 茅taient repr茅sent茅es, constituant le quorum. Tous les candidats au conseil figurant dans la procuration ont 茅t茅 茅lus, avec des votes 'pour' individuels g茅n茅ralement compris entre environ 18,7 millions et 18,94 millions, et 10,294,600 votes non exprim茅s par des courtiers enregistr茅s pour ces 茅lections.
Les actionnaires ont approuv茅 plusieurs propositions importantes : l'autorisation d'茅mettre potentiellement jusqu'脿 $50,0 millions d'actions ordinaires (plus jusqu'脿 $1,0 millions en tant que frais d'engagement) 脿 Lincoln Park Capital en vertu de l'accord d'achat du 17 juin 2025 ; le pouvoir discr茅tionnaire pour le conseil d'effectuer un regroupement d'actions (reverse stock split) 脿 un ratio compris entre 1 pour 2 et 1 pour 250 ; une approbation consultative de la r茅mun茅ration des dirigeants nomm茅s ; et la cinqui猫me modification et refonte du Plan d'incitation en actions de 2020.
Plus Therapeutics berichtete 眉ber die Ergebnisse seiner Hauptversammlung am 7. August 2025. Von den zum Stichtag 18. Juni 2025 ausstehenden 60,490,101 Aktien waren 29,973,272 Aktien vertreten, womit ein Quorum gegeben war. Alle in der Vollmacht aufgef眉hrten Direktorkandidaten wurden gew盲hlt; die einzelnen 'Zustimmungs'-Stimmen lagen allgemein im Bereich von ca. 18,7 Millionen bis 18,94 Millionen, und f眉r diese Direktorwahlen wurden 10,294,600 Broker-Non-Votes verzeichnet.
Die Aktion盲re stimmten mehreren wesentlichen Vorschl盲gen zu: die Erm盲chtigung zur m枚glichen Ausgabe von bis zu $50,0 Millionen Stammaktien (zuz眉glich bis zu $1,0 Millionen als Verpflichtungsgeb眉hr) an Lincoln Park Capital gem盲脽 dem Kaufvertrag vom 17. Juni 2025; die Erm盲chtigung des Vorstands, nach eigenem Ermessen eine Aktienzusammenlegung (Reverse Stock Split) in einem Verh盲ltnis zwischen 1 zu 2 und 1 zu 250 durchzuf眉hren; eine verbindliche beratende Zustimmung zur Verg眉tung der namentlich genannten F眉hrungskr盲fte; sowie die f眉nfte 脛nderung und Neufassung des Aktienanreizplans 2020.
- Shareholder approval of the potential issuance enabling up to $50.0 million in common stock sales to Lincoln Park under the purchase agreement
- Authorization for the board to implement a reverse stock split within a defined range (1-for-2 to 1-for-250), providing flexibility over share structure
- All nominated directors were elected, confirming the board slate
- Approval of the fifth amendment and restatement of the 2020 Stock Incentive Plan, updating equity compensation framework
- Potential dilution from the authorized issuance of up to $50.0 million of common stock to Lincoln Park, which could increase shares outstanding if utilized
- Broad reverse-split range (up to 1-for-250) could materially reduce the outstanding share count if the board elects to implement a high-ratio split
- Low shareholder participation: only 29,973,272 of 60,490,101 shares were represented at the meeting, and several proposals show significant broker non-votes (notably 10,294,600)
Insights
TL;DR Stockholders granted significant corporate authorities: a financing issuance to Lincoln Park and broad reverse-split discretion.
The issuance approval authorizes the company to sell up to $50.0 million of common stock plus up to $1.0 million as a commitment fee to Lincoln Park Capital under the existing purchase agreement. This provides the board with a financing mechanism that was expressly ratified by shareholders for Nasdaq rule compliance. The reverse split authorization permits the board to combine shares at any ratio from 1-for-2 up to 1-for-250, giving broad flexibility over capital structure. Shareholder turnout showed 29,973,272 votes cast out of 60,490,101 outstanding shares, and meaningful broker non-votes appeared on several proposals, which affected vote totals.
TL;DR Meeting outcomes are material: financing authority and reverse-split power were approved; both can alter share count and capital available.
The issuance vote passed with 18,469,325 votes in favor and 1,114,462 against, with 94,885 abstentions and 10,294,600 broker non-votes recorded. The reverse split was approved decisively with 25,678,339 votes for and 4,151,673 against (no broker non-votes on that item). Advisory compensation and the amended stock incentive plan were also approved, with vote tallies reflected in the filing. These are material governance actions that give the board tools to address capital and listing matters; the filing documents the precise vote counts for investor review.
Plus Therapeutics ha comunicato i risultati della sua assemblea annuale del 7 agosto 2025. Delle 60,490,101 azioni in circolazione alla data di record del 18 giugno 2025, sono state rappresentate 29,973,272 azioni, costituendo il quorum. Tutti i candidati al consiglio indicati nella delega sono stati eletti, con voti 'a favore' individuali generalmente compresi tra 18,7 milioni e 18,94 milioni e con 10,294,600 voti non espressi dai broker registrati per quelle elezioni.
Gli azionisti hanno approvato diverse proposte rilevanti: l'autorizzazione a emettere potenzialmente fino a $50,0 milioni di azioni ordinarie (pi霉 fino a $1,0 milioni come commissione di impegno) a Lincoln Park Capital ai sensi dell'accordo d'acquisto del 17 giugno 2025; l'autorit脿 discrezionale per il consiglio di effettuare un raggruppamento azionario a un rapporto compreso tra 1 contro 2 e 1 contro 250; un'approvazione consultiva della remunerazione dei dirigenti nominati; e la quinta modifica e riformulazione del Piano di Incentivi Azionari 2020.
Plus Therapeutics inform贸 los resultados de su junta anual del 7 de agosto de 2025. De las 60,490,101 acciones en circulaci贸n en la fecha de registro del 18 de junio de 2025, se representaron 29,973,272 acciones, constituyendo qu贸rum. Todos los candidatos al consejo incluidos en el poder fueron elegidos, con votos 'a favor' individuales generalmente en el rango de 18,7 millones a 18,94 millones y con 10,294,600 votos no emitidos por los intermediarios registrados en esas elecciones.
Los accionistas aprobaron varias propuestas importantes: la autorizaci贸n para emitir potencialmente hasta $50,0 millones de acciones ordinarias (m谩s hasta $1,0 millones como comisi贸n de compromiso) a Lincoln Park Capital seg煤n el acuerdo de compra del 17 de junio de 2025; la facultad discrecional del consejo para llevar a cabo una consolidaci贸n inversa de acciones en cualquier proporci贸n entre 1 por 2 y 1 por 250; la aprobaci贸n consultiva de la remuneraci贸n de los directivos nombrados; y la quinta enmienda y reformulaci贸n del Plan de Incentivos en Acciones de 2020.
Plus Therapeutics電� 2025雲� 8鞗� 7鞚� 鞐半 欤检＜齑濏殞 瓴瓣臣毳� 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 18鞚� 旮办鞙茧 氚滍枆欤检嫕靾� 60,490,101欤� 欷� 29,973,272欤缄皜 雽�響滊悩鞏� 鞝曥”靾橁皜 靹彪霅橃棃鞀惦媹雼�. 鞙勳瀯鞛レ棎 旮办灛霅� 氇摖 鞚挫偓 頉勲炒臧� 靹犾瀯霅橃棃鞙茧┌, 臧滊硠 '彀劚' 響滊姅 雽�觳措 鞎� 1,870毵寏1,894毵�欤� 氩旍渼鞓�瓿� 頃措嫻 鞚挫偓 靹犼卑鞐愳劀電� 10,294,600瓯挫潣 欷戧皽鞚�(敫岆旎�) 氙疙埇響滉皜 旮半霅橃棃鞀惦媹雼�.
欤检＜霌れ潃 鞐煬 欤检殧 鞎堦贝鞚� 鞀轨澑頄堨姷雼堧嫟. 2025雲� 6鞗� 17鞚� 毵れ垬瓿勳暯鞐� 霐半澕 Lincoln Park Capital鞐� 雽�頃� 氤错喌欤� 斓滊寑 $50.0 million(毂呾瀯 靾橃垬耄岆 斓滊寑 $1.0 million 於旉皜 臧�電�)鞚� 氚滍枆頃� 靾� 鞛堧姅 鞀轨澑; 鞚挫偓須岅皜 1雽赌2鞐愳劀 1雽赌250 靷澊鞚� 牍勳湪搿� 鞏胳牅霌犾 欤检嫕 氤戫暕(鞐硲頃�)鞚� 鞁ろ枆頃� 靾� 鞛堧姅 鞛焿甓�; 歆�氇� 鞛勳洂鞚� 氤挫垬鞐� 雽�頃� 甓岅碃鞝� 鞀轨澑; 氚� 2020雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉鞚� 鞝�5彀� 臧滌爼 氚� 鞛瀾靹� 霌膘澊 韽暔霅╇媹雼�.
Plus Therapeutics a annonc茅 les r茅sultats de son assembl茅e annuelle du 7 ao没t 2025. Sur les 60,490,101 actions en circulation 脿 la date d'enregistrement du 18 juin 2025, 29,973,272 actions 茅taient repr茅sent茅es, constituant le quorum. Tous les candidats au conseil figurant dans la procuration ont 茅t茅 茅lus, avec des votes 'pour' individuels g茅n茅ralement compris entre environ 18,7 millions et 18,94 millions, et 10,294,600 votes non exprim茅s par des courtiers enregistr茅s pour ces 茅lections.
Les actionnaires ont approuv茅 plusieurs propositions importantes : l'autorisation d'茅mettre potentiellement jusqu'脿 $50,0 millions d'actions ordinaires (plus jusqu'脿 $1,0 millions en tant que frais d'engagement) 脿 Lincoln Park Capital en vertu de l'accord d'achat du 17 juin 2025 ; le pouvoir discr茅tionnaire pour le conseil d'effectuer un regroupement d'actions (reverse stock split) 脿 un ratio compris entre 1 pour 2 et 1 pour 250 ; une approbation consultative de la r茅mun茅ration des dirigeants nomm茅s ; et la cinqui猫me modification et refonte du Plan d'incitation en actions de 2020.
Plus Therapeutics berichtete 眉ber die Ergebnisse seiner Hauptversammlung am 7. August 2025. Von den zum Stichtag 18. Juni 2025 ausstehenden 60,490,101 Aktien waren 29,973,272 Aktien vertreten, womit ein Quorum gegeben war. Alle in der Vollmacht aufgef眉hrten Direktorkandidaten wurden gew盲hlt; die einzelnen 'Zustimmungs'-Stimmen lagen allgemein im Bereich von ca. 18,7 Millionen bis 18,94 Millionen, und f眉r diese Direktorwahlen wurden 10,294,600 Broker-Non-Votes verzeichnet.
Die Aktion盲re stimmten mehreren wesentlichen Vorschl盲gen zu: die Erm盲chtigung zur m枚glichen Ausgabe von bis zu $50,0 Millionen Stammaktien (zuz眉glich bis zu $1,0 Millionen als Verpflichtungsgeb眉hr) an Lincoln Park Capital gem盲脽 dem Kaufvertrag vom 17. Juni 2025; die Erm盲chtigung des Vorstands, nach eigenem Ermessen eine Aktienzusammenlegung (Reverse Stock Split) in einem Verh盲ltnis zwischen 1 zu 2 und 1 zu 250 durchzuf眉hren; eine verbindliche beratende Zustimmung zur Verg眉tung der namentlich genannten F眉hrungskr盲fte; sowie die f眉nfte 脛nderung und Neufassung des Aktienanreizplans 2020.
FAQ
What did Plus Therapeutics (PSTV) shareholders approve at the August 7, 2025 meeting?
How many Plus Therapeutics (PSTV) shares were outstanding and how many voted?
What vote totals approved the issuance to Lincoln Park for PSTV?
What reverse split authority did PSTV shareholders grant?
Were executive compensation and the stock incentive plan approved for PSTV?
